Swiss psychoanalyst Hermann Rorschach formalized this idea through the inkblot test he created—he noticed that people with schizophrenia tended to perceive the images differently than did other ...

The phase 2 trial represented a key test of that idea ... after five weeks in a phase 3 trial that enrolled 256 people with schizophrenia experiencing acute psychosis. Neurocrine Biosciences ...

Schizophrenia is a serious mental disorder that affects around 1% of the world's population. Researchers at the University of Barcelona have identified a deficit in contrast perception in people with ...

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

An emerging field of genetics promises to let parents choose the “healthiest” baby.

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

There are as yet no effective drugs for negative symptoms like social withdrawal and lack of motivation. Read more at ...